Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenocarcinoma × catumaxomab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Carcinoma, Ovarian Epithelial 4 Stomach Neoplasms 3 Peritoneal Neoplasms 3 Fallopian Tube Neoplasms 3 Carcinoma 3 Urinary Bladder Neoplasms 2 Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Glandular and Epithelial 1 Ascites 1 Adenocarcinoma 1

Interventions

Oxaliplatin 42 Gemcitabine 38 Fluorouracil 36 Capecitabine 28 pembrolizumab 25 Leucovorin 25 Docetaxel 24 Cisplatin 22 Paclitaxel 18 Carboplatin 16 Bevacizumab 15 Pemetrexed 14 130-nm albumin-bound paclitaxel 14 Radiotherapy 13 Irinotecan 13 Albumin-Bound Paclitaxel 11 Nivolumab 10 Ramucirumab 9 Cyclophosphamide 9 Trastuzumab 7 Radiosurgery 7 Drug Therapy 6 zolbetuximab 5 trastuzumab deruxtecan 5 durvalumab 5 Taxes 5 Sorafenib 5 S 1 (combination) 5 Metformin 5 Everolimus 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01504256 2018-01-23

CatuNeo

AIO-Studien-gGmbH

Phase 2 Completed

Adenocarcinoma, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡